Jefferies Reiterates a 'Buy' on China Cord Blood (CO); Tying The Knot with Cordlife

Jefferies reiterates a 'Buy' on China Cord Blood (NYSE: CO) price target of $5.50.

Analyst, Brian Tanquilut, said, "CO's decision to buy out the minority position in its Guangzhou operations and enhance its relationship with Asia-wide cord blood bank operator Cordlife at the same time, is a strategic move that cleans up CO's operating structure and provides an earnings boost (through the reduction of CO's non-controlling interest accrual) and incremental cash to fund share buybacks."

For an analyst ratings summary and ratings history on China Cord Blood click here. For more ratings news on China Cord Blood click here.

Shares of China Cord Blood closed at $2.65 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Cisco rating cut at HSBC as analyst sees a lack of catalysts